SPECTRUM PHARMACEUTICALS INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Cash Flows From Operating Activities:
Loss from continuing operations
Income (loss) from discontinued operations, net of income taxes
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Amortization of debt discount
Amortization of deferred financing costs on 2018 Convertible Notes, recorded to interest expense (Note 15)
Stock-based compensation
Impairment of second source manufacturer
Recognized gain on Commercial Product Portfolio Transaction
Amortization of operating leases (Note 10(a))
Loss on disposal of manufacturing equipment
Non-cash lease expense
Amortization of premium (discount) on debt securities
Realized gain on mutual funds
Income tax recognition on unrealized gain on available-for-sale securities
Realized loss (gain) on mutual funds
Realized loss (gain) on sale of equity holdings
Unrealized loss on equity holdings
Unrealized loss from transactions denominated in foreign currency
Change in deferred tax liabilities
Income tax recognition on unrealized gain for available-for-sale securities
Unrealized gains on marketable securities (Note 3(a))
Change in fair value of contingent consideration related to the Talon and EVOMELA acquisitions (Note 10)
Research and development expense recognized for the value of common stock issued in connection with QAPZOLA (Note 17(b)(x)) and ROLONTIS (Note 17(b)(xiii)) milestone achievements
Change in fair value of contingent consideration
Bad debt expense (recovery)
Loss on 2018 Convertible Note purchase (Note 9)
Change in cash surrender value of corporate-owned life insurance policy
Other non-cash items
Loss on disposal of assets

Changes in operating assets and liabilities:
Accounts receivable, net
Other receivables
Inventories
Prepaid expenses and other current assets
Other assets
Accounts payable and other accrued liabilities
Accrued payroll and benefits
FOLOTYN development liability
Acquisition-related contingent obligations
Contract liabilities
Other long-term liabilities
Deferred revenue

Net cash used in operating activities
Cash Flows From Investing Activities:
Proceeds from Commercial Product Portfolio Transaction
Proceeds from maturities of investments
Proceeds from sale of equity holdings
Purchases of investments
Purchases of property and equipment, net
Proceeds from sale of property and equipment, net
Proceeds from redemption of corporate-owned life insurance policy
Cash paid for KHAPZORY distribution rights
Payment for corporate-owned life insurance premiums
Purchase of equity securities (Note 8)
Net cash (used in) provided by investing activities

Cash Flows From Financing Activities:
Proceeds from the issuance of debt, net of debt acquisition costs
Issuance of common shares to Hanmi Pharmaceutical Co., Ltd.
Proceeds from sale of common stock under an at-the-market sales agreement, net
Public Offering
At-the-market Sales Agreement
Total proceeds from sale of common stock under an at-the-market sales agreement, net

Dividends paid upon conversion of Series E Convertible Voting Preferred Stock (Note 7)
Proceeds from employees, for our remittance to tax authorities, upon vesting of restricted stock and upon exercises of stock options
Payments to tax authorities upon employees' surrender of restricted stock upon vesting and upon exercises of stock options
Payment of principal upon the maturity of the 2018 Convertible Notes (Note 9)
Payment of contingent consideration related to EVOMELA acquisition (Note 10(b))
Purchase of 2018 Convertible Notes (Note 9)
Purchase of warrants related to the conversion hedge of 2018 Convertible Notes (Note 9)
Proceeds from sale of call options related to the conversion hedge of 2018 Convertible Notes (Note 9)
Proceeds from employees for exercises of stock options
Proceeds from sale of stock under employee stock purchase plan
Proceeds from employees, for our remittance to tax authorities, upon vesting of restricted stock
Net cash provided by financing activities

Effect of exchange rates on cash and equivalents
Effect of exchange rates on cash and cash equivalents
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents — beginning of year
Cash and cash equivalents — end of year
Supplemental Disclosure of Cash Flow Information:
Cash paid for facility and equipment under operating leases
Cash paid for income taxes
Cash paid for income taxes
Additions of property and equipment that remain in accounts payable and other accrued liabilities
Cash paid for interest
Supplemental disclosure of cash flow information-Non-cash:
Issuance of warrants in connection with debt financing

Comments